Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Perrigo Company plc (NYSE: PRGO).

Full DD Report for PRGO

You must become a subscriber to view this report.


Recent News from (NYSE: PRGO)

Your Daily Scoop: Five Prime Progresses, Endocyte's rPFS And Stock Offering, Tracon's Results Published
Stocks in News: FPRX, ECYT Five Prime launches late-stage study of bemarituzumab + chemo in gastric cancer or GEJ Discussion : Five Prime Therapeutics' ( FPRX ) FPA144 (bemarituzumab) plus chemotherapy completed Part 1 of a Phase 1/3 clinical trial evaluating treatment-naive patients ...
Source: SeekingAlpha
Date: September, 12 2018 13:55
Nostrum Labs hikes price of mature antibiotic 400%
In a move that would make Martin Shkreli proud, privately held Nostrum Laboratories has increased the price of antibiotic nitrofurantoin, on the market since 1953 to treat bladder infections, 400%. A bottle of the pills now costs $2,393, up from ~$475. More news on: Amneal Pharmaceutical...
Source: SeekingAlpha
Date: September, 12 2018 11:50
Senate vote approaches on bill to combat opioid crisis
The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news...
Source: SeekingAlpha
Date: September, 07 2018 12:48
Perrigo Announces Final FDA Approval and Planned Launch for the Store Brand OTC Equivalent of Imodium® Multi-Symptom Relief
DUBLIN , Sept. 7, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug administration for the store brand over-the-counter (OTC) equivalent of Imodium ® Multi-Symptom Relief (loperamide h...
Source: PR Newswire
Date: September, 07 2018 09:05
Tracking David Einhorn's Portfolio - Q2 2018 Update
This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn's Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking David Einhorn's Greenlight Capital Hol...
Source: SeekingAlpha
Date: September, 02 2018 12:34

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1059.8158.8459.8157.70878,208
2018-12-0762.3259.9362.6659.671,129,933
2018-12-0663.0962.6263.6061.991,893,258
2018-12-0463.5562.8464.2762.731,401,104
2018-12-0363.1163.4563.8062.87861,370,586

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1018,35629,36662.5077Short
2018-12-073,35611,27129.7755Cover
2018-12-0614,16726,66753.1256Short
2018-12-044,64814,37732.3294Cover
2018-12-037,82275,99810.2924Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PRGO.


About Perrigo Company plc (NYSE: PRGO)

Logo for Perrigo Company plc (NYSE: PRGO)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $10,417,889,307 - 05/25/2018
  • Issue and Outstanding: 138,462,112 - 05/04/2018

 


Recent Filings from (NYSE: PRGO)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 09 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: August, 01 2018
An annual report of employee stock purchase savings and similar plans
Filing Type: 11-KFiling Source: edgar
Filing Date: June, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 23 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 23 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 09 2018

 

 


Daily Technical Chart for (NYSE: PRGO)

Daily Technical Chart for (NYSE: PRGO)


Stay tuned for daily updates and more on (NYSE: PRGO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: PRGO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PRGO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PRGO and does not buy, sell, or trade any shares of PRGO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/